about
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinomaHigh class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo.A prognostic gene expression index in ovarian cancer - validation across different independent data sets.Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network.Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study.Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancerAn intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas.Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypesNeutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer.Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimizationRole of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortiumAccumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas.Neutrophil Granulocytes in Ovarian Cancer - Induction of Epithelial-To-Mesenchymal-Transition and Tumor Cell Migration.Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas.HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancerIdentification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapyAnti-cancer immune response mechanisms in neoadjuvant and targeted therapy.Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis.Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer.Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCAn illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.Expression of classical NF-kappaB pathway effectors in human ovarian carcinoma.Prognostic impact of AMP-activated protein kinase expression in ovarian carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics.Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis.Neuroendocrine Neoplasms of the Ovary: A Retrospective Study of the North Eastern German Society of Gynecologic Oncology (NOGGO).Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.PDK1 is Expressed in Ovarian Serous Carcinoma and Correlates with Improved Survival in High-grade Tumors.Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
P50
Q27853285-850401C8-5484-4AE4-922C-C21E687AE006Q30884835-DEA303B2-3725-447B-A40A-64D25851D654Q33419209-261C0F14-1272-4095-BE5D-953374B4EBE2Q33457920-7DA2565E-3F65-4AF7-9789-2D39FC2877AAQ33459478-85E46DB1-E1B9-446D-B379-0851EBABB132Q33459521-53050D2C-73A4-4999-9B9A-11C3F63B30CFQ33829751-D1E1B5E2-357E-4781-B9A3-901F1B3D01C9Q33917340-7ABD895E-675A-44A2-ACC1-68D73490055FQ33960748-A250EF00-029B-4573-B109-60378DBB4364Q34006749-5C1BF5D7-F2D1-4581-A468-8A9E9F92E46DQ34440998-3B5C72AD-14D6-40DA-A41D-10229FEC0BC8Q35060987-E6D8BF69-C8AC-4E3A-ABC5-0737E52A95DEQ36467712-2D36DE3F-9F8E-45FE-B505-5B66D0768165Q36498614-D3E6A180-EF71-4DDF-BA30-4AA69CBDAE82Q36603235-B19B9ECB-4C7D-42AE-A2F8-9A86438C5EEBQ36764923-7CE7FFE1-D349-4F10-8823-FA1BC559A021Q36840303-6B414AA2-0FB1-48B5-A425-31E7CBDE9BA2Q36903047-1E9A0E56-A2EC-4DC6-8AD0-34A08EAED4BAQ37467199-EB634ACA-C2C9-4492-B215-2994872BAAF2Q37866150-33896BF1-A9CA-466C-8EF7-C7FE7DA9E6F4Q38422475-F789A5CD-3FBB-49CA-B2F5-EEF54B65704AQ38744076-E1ED9FFF-483B-4B74-BEA8-E4BD1131B3F2Q38774230-18F3E6C7-6138-495C-9CBF-49D3A2326CB6Q39630646-CC943DAE-914E-4432-9098-F70CBEF46727Q39693444-96F91A8D-49BB-4480-B6F8-5CA77B780A1FQ39789349-4B5B69A2-7175-47E5-BAFE-0D0DBC765AD2Q39914477-518698B3-1036-454B-92A8-1D19DDBB697DQ39920477-AA544822-C645-4444-957F-EF8974D87AE7Q40154485-9EBA1E82-2D9E-4553-92B5-A95911CAA533Q40389999-1A0834D2-6A39-48D2-8E06-B59CAE008AB4Q40443875-3AC44153-705F-4EAA-8D32-5493F786A42AQ40914660-8A224051-1C67-4034-B92F-1E8FB796D316
P50
description
onderzoeker
@nl
name
Silvia Darb-Esfahani
@ast
Silvia Darb-Esfahani
@en
Silvia Darb-Esfahani
@es
Silvia Darb-Esfahani
@sl
type
label
Silvia Darb-Esfahani
@ast
Silvia Darb-Esfahani
@en
Silvia Darb-Esfahani
@es
Silvia Darb-Esfahani
@sl
prefLabel
Silvia Darb-Esfahani
@ast
Silvia Darb-Esfahani
@en
Silvia Darb-Esfahani
@es
Silvia Darb-Esfahani
@sl